All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Correlation between IGF-I and chemotherapy-related toxicities in childhood ALL
|
An evaluation of the role of IGF-I in children with ALL undergoing chemotherapy has been published in the International Journal of Molecular Sciences by Kocadag et al.1 This study investigated the fluctuations in IGF-I levels during treatment and how this correlated with tissue damage and inflammation. These data were used to determine the potential for IGF-I to be used as a biomarker for chemotherapy-related toxicities.1 |
| Key learnings |
|
IGF-I levels were found to be significantly reduced at diagnosis but then increased after chemotherapy initiation, peaking on Day 8. This rise indicates an IGF-I response to chemotherapy-induced tissue damage. |
|
Increases in IGF-I were positively correlated with inflammatory markers, including CRP and IL-6, suggesting that IGF-I may indicate systemic inflammation. |
|
Among patients with a larger increase in IGF-I from Day 1 to Day 15, there was a correlation with a slower recovery from chemotherapy-induced intestinal damage. |
|
Patients with higher IGF-I levels on Day 8 had an increased likelihood of severe intestinal mucositis on Day 15 (p = 0.02). |
|
These data suggest IGF-I may be feasible as an early biomarker for chemotherapy-induced tissue injury and systemic inflammation, with potential to guide treatment strategies in childhood ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; CRP, C-reactive protein; IGF-I, insulin-like growth factor-I; IL, interleukin.
- Kocadag H, Weischendorff S, De Pietri S, et al. Upregulation of insulin-like growth factor-I in response to chemotherapy in children with acute lymphoblastic leukemia. Int J Mol Sci. 2024;25(17):9582. DOI: 3390/ijms25179582
More about...
Your opinion matters
2 votes - 6 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox